{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T01:06:01Z","timestamp":1762045561033,"version":"build-2065373602"},"reference-count":149,"publisher":"Bentham Science Publishers Ltd.","issue":"16","funder":[{"DOI":"10.13039\/100000050","name":"NHLBI, National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["RO1HL076801"],"award-info":[{"award-number":["RO1HL076801"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"NIDCR, National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["RO1DE014079"],"award-info":[{"award-number":["RO1DE014079"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The SARS-CoV-2 enters the human airways and comes into contact with the mucous membranes lining the mouth, nose, and eyes. The virus enters the healthy cells and uses cell machinery to make several copies itself. Critically ill patients infected with SARS-CoV-2 may have damaged lungs, air sacs, lining, and walls. Since COVID-19 causes cytokine storm, it damages the alveolar cells of the lungs and fills them with fluid, making it harder to exchange oxygen and carbon dioxide. The SARS-CoV-2 infection causes a range of complications, including mild to critical breathing difficulties. It has been observed that older people suffering from health conditions like cardiomyopathies, nephropathies, metabolic syndrome, and diabetes instigate severe symptoms. Many people who died due to COVID-19 had impaired metabolic health [IMH], characterized by hypertension, dyslipidemia, and hyperglycemia, i.e., diabetes, cardiovascular system, and renal diseases, making their retrieval challenging. Jeopardy stresses for increased mortality from COVID-19 include older age, COPD, ischemic heart disease, diabetes mellitus, and immunosuppression. However, no targeted therapies are available as of now. Almost two-thirds of diagnosed coronavirus patients had cardiovascular diseases and diabetes, out of which 37% were under 60. The NHS audit revealed that with a higher expression of ACE-2 receptors, viral particles could easily bind their protein spikes and get inside the cells, finally causing COVID-19 infection. Hence, people with IMH are more prone to COVID-19 and, ultimately, comorbidities. This review provides enormous information about tissue [lungs, heart, and kidneys] damage, pathophysiological changes, and impaired metabolic health of SARS-CoV-2 infected patients. Moreover, it also designates the possible therapeutic targets of COVID-19 and drugs which can be used against these targets.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557522666220201154845","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T04:24:03Z","timestamp":1643775843000},"page":"2102-2123","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["SARS-CoV-2 Infections, Impaired Tissue, and Metabolic Health: Pathophysiology and Potential Therapeutics"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8089-040X","authenticated-orcid":true,"given":"Shailendra Pratap","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pharmacology, New York Medical College, Valhalla 10595, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Kanwal","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, Punjab 151001, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salomon","family":"Amar","sequence":"first","affiliation":[{"name":"Department of Pharmacology, New York Medical College, Valhalla 10595, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aayushi","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer, Rajasthan 305817, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujeet Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer, Rajasthan 305817, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjib K.","family":"Patra","sequence":"additional","affiliation":[{"name":"Department of Yoga, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer, Rajasthan 305817, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navjot","family":"Kanwar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, Punjab 151001, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranata","family":"Manna","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer, Rajasthan 305817, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1","volume":"182","author":"Weis N.","year":"2020","unstructured":"Weis N.; Thorsteinsson K.; Martinussen C.; Madsbad S.; The endocrine and metabolic link between COVID-19, diabetes and obesity Ugeskr Laeger 2020,182(29),1-8","journal-title":"Ugeskr Laeger"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjms.2020.10.002","volume":"361","author":"Chang W.T.","year":"2021","unstructured":"Chang W.T.; Toh H.S.; Liao C.T.; Yu W.L.; Cardiac involvement of COVID-19: A comprehensive review. Am J Med Sci 2021,361(1),14-22","journal-title":"Am J Med Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamacardio.2020.1286","volume":"5","author":"Madjid M.","year":"2020","unstructured":"Madjid M.; Safavi-Naeini P.; Solomon S.D.; Vardeny O.; Potential effects of coronaviruses on the cardiovascular system: A review. JAMA Cardiol 2020,5(7),831-840","journal-title":"JAMA Cardiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.120.046941","volume":"141","author":"Clerkin K.J.","year":"2020","unstructured":"Clerkin K.J.; Fried J.A.; Raikhelkar J.; Sayer G.; Griffin J.M.; Masoumi A.; Jain S.S.; Burkhoff D.; Kumaraiah D.; Rabbani L.; Schwartz A.; Uriel N.; COVID-19 and cardiovascular disease. Circulation 2020,141(20),1648-1655","journal-title":"Circulation"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/postgradmedj-2020-138386","volume":"97","author":"Adil M.T.","year":"2021","unstructured":"Adil M.T.; Rahman R.; Whitelaw D.; Jain V.; Al-Taan O.; Rashid F.; Munasinghe A.; Jambulingam P.; SARS-CoV-2 and the pandemic of COVID-19. Postgrad Med J 2021,97(1144),110-116","journal-title":"Postgrad Med J"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1021\/acs.molpharmaceut.0c00608","volume":"18","author":"Salian V.S.","year":"2021","unstructured":"Salian V.S.; Wright J.A.; Vedell P.T.; Nair S.; Li C.; Kandimalla M.; Tang X.; Carmona Porquera E.M.; Kalari K.R.; Kandimalla K.K.; COVID-19 transmission, current treatment, and future therapeutic strategies. Mol Pharm 2021,18(3),754-771","journal-title":"Mol Pharm"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"Yang X.","year":"2020","unstructured":"Yang X.; Yu Y.; Xu J.; Shu H.; Xia J.; Liu H.; Wu Y.; Zhang L.; Yu Z.; Fang M.; Yu T.; Wang Y.; Pan S.; Zou X.; Yuan S.; Shang Y.; Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020,8(5),475-481","journal-title":"Lancet Respir Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"Guan W.J.","year":"2020","unstructured":"Guan W.J.; Ni Z.Y.; Hu Y.; Liang W.H.; Ou C.Q.; He J.X.; Liu L.; Shan H.; Lei C.L.; Hui D.S.C.; Du B.; Li L.J.; Zeng G.; Yuen K.Y.; Chen R.C.; Tang C.L.; Wang T.; Chen P.Y.; Xiang J.; Li S.Y.; Wang J.L.; Liang Z.J.; Peng Y.X.; Wei L.; Liu Y.; Hu Y.H.; Peng P.; Wang J.M.; Liu J.Y.; Chen Z.; Li G.; Zheng Z.J.; Qiu S.Q.; Luo J.; Ye C.J.; Zhu S.Y.; Zhong N.S.; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020,382(18),1708-1720","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/all.14238","volume":"75","author":"Zhang J-J.","year":"2020","unstructured":"Zhang J-J.; Dong X.; Cao Y-Y.; Yuan Y.D.; Yang Y.B.; Yan Y.Q.; Akdis C.A.; Gao Y.D.; Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020,75(7),1730-1741","journal-title":"Allergy"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e00127","DOI":"10.1128\/JVI.00127-20","volume":"94","author":"Wan Y.","year":"2020","unstructured":"Wan Y.; Shang J.; Graham R.; Baric R.S.; Li F.; Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020,94(7),e00127-e20","journal-title":"J Virol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.phrs.2017.06.005","volume":"125","author":"Li X.C.","year":"2017","unstructured":"Li X.C.; Zhang J.; Zhuo J.L.; The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases Pharmacol Res 2017,125(Pt A),21-38","journal-title":"The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases Pharmacol Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"Fang L.","year":"2020","unstructured":"Fang L.; Karakiulakis G.; Roth M.; Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020,8(4),e21","journal-title":"Lancet Respir Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","volume":"14","author":"Astuti I.","year":"2020","unstructured":"Astuti I.; Ysrafil., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr 2020,14(4),407-412","journal-title":"Diabetes Metab Syndr"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41379-020-0536-x","volume":"33","author":"Tian S.","year":"2020","unstructured":"Tian S.; Xiong Y.; Liu H.; Niu L.; Guo J.; Liao M.; Xiao S.Y.; Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 2020,33(6),1007-1014","journal-title":"Mod Pathol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/ageing\/afaa093","volume":"49","author":"Lithander F.E.","year":"2020","unstructured":"Lithander F.E.; Neumann S.; Tenison E.; Lloyd K.; Welsh T.J.; Rodrigues J.C.L.; Higgins J.P.T.; Scourfield L.; Christensen H.; Haunton V.J.; Henderson E.J.; COVID-19 in older people: A rapid clinical review. Age Ageing 2020,49(4),501-515","journal-title":"Age Ageing"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"9959","DOI":"10.18632\/aging.103344","volume":"12","author":"Mueller A.L.","year":"2020","unstructured":"Mueller A.L.; McNamara M.S.; Sinclair D.A.; Why does COVID-19 disproportionately affect older people? Aging (Albany NY) 2020,12(10),9959-9981","journal-title":"Aging (Albany NY)"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2000607","DOI":"10.1183\/13993003.00607-2020","volume":"55","author":"Mason R.J.","year":"2020","unstructured":"Mason R.J.; Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J 2020,55(4),2000607","journal-title":"Eur Respir J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00292-021-00918-9","volume":"42","author":"Ackermann M.","year":"2021","unstructured":"Ackermann M.; Werlein C.; L\u00e4nger F.; K\u00fchnel M.P.; Jonigk D.D.; COVID-19: Effects on the lungs and heart. Pathologe 2021,42(2),164-171","journal-title":"Pathologe"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1515\/dx-2020-0057","volume":"7","author":"Ciaccio M.","year":"2020","unstructured":"Ciaccio M.; Agnello L.; Biochemical biomarkers alterations in Coronavirus disease 2019 (COVID-19). Diagnosis (Berl) 2020,7(4),365-372","journal-title":"Diagnosis (Berl)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jtho.2020.02.010","volume":"15","author":"Tian S.","year":"2020","unstructured":"Tian S.; Hu W.; Niu L.; Liu H.; Xu H.; Xiao S-Y.; Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020,15(5),700-704","journal-title":"J Thorac Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Xu Z.","year":"2020","unstructured":"Xu Z.; Shi L.; Wang Y.; Zhang J.; Huang L.; Zhang C.; Liu S.; Zhao P.; Liu H.; Zhu L.; Tai Y.; Bai C.; Gao T.; Song J.; Xia P.; Dong J.; Zhao J.; Wang F.S.; Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020,8(4),420-422","journal-title":"Lancet Respir Med"},{"key":"ref=22","author":"Luo W.","year":"2020","unstructured":"Luo W.; Yu H.; Gou J.; Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19): pulmonary fibrosis and vascular changes including microthrombosis formation Preprints 2020","journal-title":"Preprints"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12931-021-01625-y","volume":"22","author":"Truffaut L.","year":"2021","unstructured":"Truffaut L.; Demey L.; Bruyneel A.V.; Roman A.; Alard S.; De Vos N.; Bruyneel M.; Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission. Respir Res 2021,22(1),29","journal-title":"Respir Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1164\/rccm.202008-3265OC","volume":"203","author":"Dorward D.A.","year":"2021","unstructured":"Dorward D.A.; Russell C.D.; Um I.H.; Elshani M.; Armstrong S.D.; Penrice-Randal R.; Millar T.; Lerpiniere C.E.B.; Tagliavini G.; Hartley C.S.; Randle N.P.; Gachanja N.N.; Potey P.M.D.; Dong X.; Anderson A.M.; Campbell V.L.; Duguid A.J.; Al Qsous W.; BouHaidar R.; Baillie J.K.; Dhaliwal K.; Wallace W.A.; Bellamy C.O.C.; Prost S.; Smith C.; Hiscox J.A.; Harrison D.J.; Lucas C.D.; Tissue-specific immunopathology in fatal COVID-19. Am J Respir Crit Care Med 2021,203(2),192-201","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/ajcp\/aqaa062","volume":"153","author":"Barton L.M.","year":"2020","unstructured":"Barton L.M.; Duval E.J.; Stroberg E.; Ghosh S.; Mukhopadhyay S.; COVID-19 autopsies, oklahoma, USA. Am J Clin Pathol 2020,153(6),725-733","journal-title":"Am J Clin Pathol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.acra.2020.03.002","volume":"27","author":"Guan C.S.","year":"2020","unstructured":"Guan C.S.; Lv Z.B.; Yan S.; Du Y.N.; Chen H.; Wei L.G.; Xie R.M.; Chen B.D.; Imaging features of coronavirus disease 2019 (COVID-19): evaluation on thin-section CT. Acad Radiol 2020,27(5),609-613","journal-title":"Acad Radiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3174\/ajnr.A6561","volume":"41","author":"Barajas R.F.","year":"2020","unstructured":"Barajas R.F.; Rufener G.; Starkey J.; Duncan T.; Fuss C.; Asymptomatic COVID-19: what the neuroradiologist needs to know about pulmonary manifestations. AJNR Am J Neuroradiol 2020,41(6),966-968","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1007\/s00330-020-06801-0","volume":"30","author":"Ye Z.","year":"2020","unstructured":"Ye Z.; Zhang Y.; Wang Y.; Huang Z.; Song B.; Chest CT manifestations of new coronavirus disease 2019 (COVID-19): A pictorial review. Eur Radiol 2020,30(8),4381-4389","journal-title":"Eur Radiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"107228","DOI":"10.1016\/j.carpath.2020.107228","volume":"47","author":"Geng Y-J.","year":"2020","unstructured":"Geng Y-J.; Wei Z-Y.; Qian H-Y.; Huang J.; Lodato R.; Castriotta R.J.; Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. Cardiovasc Pathol Off J Soc Cardiovasc Pathol 2020,47,107228","journal-title":"Cardiovasc Pathol Off J Soc Cardiovasc Pathol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.14336\/AD.2020.1112","volume":"12","author":"de Moraes D.","year":"2021","unstructured":"de Moraes D.; Paiva B.V.B.; Cury S.S.; Ludwig R.G.; Junior J.P.A.; Mori M.A.D.S.; Carvalho R.F.; Prediction of SARS-CoV interaction with host proteins during lung aging reveals a potential role for TRIB3 in COVID-19. Aging Dis 2021,12(1),42-49","journal-title":"Aging Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e13230","DOI":"10.1111\/acel.13230","volume":"19","author":"Santesmasses D.","year":"2020","unstructured":"Santesmasses D.; Castro J.P.; Zenin A.A.; Shindyapina A.V.; Gerashchenko M.V.; Zhang B.; Kerepesi C.; Yim S.H.; Fedichev P.O.; Gladyshev V.N.; COVID-19 is an emergent disease of aging. Aging Cell 2020,19(10),e13230","journal-title":"Aging Cell"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11547-020-01202-1","volume":"125","author":"Borghesi A.","year":"2020","unstructured":"Borghesi A.; Zigliani A.; Masciullo R.; Golemi S.; Maculotti P.; Farina D.; Maroldi R.; Radiographic severity index in COVID-19 pneumonia: Relationship to age and sex in 783 Italian patients. Radiol Med (Torino) 2020,125(5),461-464","journal-title":"Radiol Med (Torino)"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"342","DOI":"10.5694\/mja2.50785","volume":"213","author":"Holt N.R.","year":"2020","unstructured":"Holt N.R.; Neumann J.T.; McNeil J.J.; Cheng A.C.; Implications of COVID-19 for an ageing population. Med J Aust 2020,213(8),342-344.e1","journal-title":"Med J Aust"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/ars.2020.8111","volume":"33","author":"Abouhashem A.S.","year":"2020","unstructured":"Abouhashem A.S.; Singh K.; Azzazy H.M.E.; Sen C.K.; Is low alveolar type II cell SOD3 in the lungs of elderly linked to the observed severity of COVID-19? Antioxid Redox Signal 2020,33(2),59-65","journal-title":"Antioxid Redox Signal"},{"key":"ref=35","author":"Booeshaghi A.S.","year":"2020","unstructured":"Booeshaghi A.S.; Pachter L.; Decrease in ACE2","journal-title":"bioRxiv"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"24620","DOI":"10.1073\/pnas.2012358117","volume":"117","author":"Steinman J.B.","year":"2020","unstructured":"Steinman J.B.; Lum F.M.; Ho P.P-K.; Kaminski N.; Steinman L.; Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. Proc Natl Acad Sci USA 2020,117(40),24620-24626","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/d41586-020-02598-6","volume":"585","author":"Marshall M.","year":"2020","unstructured":"Marshall M.; The lasting misery of coronavirus long-haulers. Nature 2020,585(7825),339-341","journal-title":"Nature"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1183\/13993003.01217-2020","volume":"55","author":"Mo X.","year":"2020","unstructured":"Mo X.; Jian W.; Su Z.; Chen M.; Peng H.; Peng P.; Lei C.; Chen R.; Zhong N.; Li S.; Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 2020,55(6),2-5","journal-title":"Eur Respir J"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S2213-2600(20)30349-0","volume":"8","author":"Raghu G.","year":"2020","unstructured":"Raghu G.; Wilson K.C.; COVID-19 interstitial pneumonia: Monitoring the clinical course in survivors. Lancet Respir Med 2020,8(9),839-842","journal-title":"Lancet Respir Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"100463","DOI":"10.1016\/j.eclinm.2020.100463","volume":"25","author":"Zhao Y-M.","year":"2020","unstructured":"Zhao Y-M.; Shang Y-M.; Song W-B.; Li Q.Q.; Xie H.; Xu Q.F.; Jia J.L.; Li L.M.; Mao H.L.; Zhou X.M.; Luo H.; Gao Y.F.; Xu A.G.; Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 2020,25,100463","journal-title":"EClinicalMedicine"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2020.12603","volume":"324","author":"Carf\u00ec A.","year":"2020","unstructured":"Carf\u00ec A.; Bernabei R.; Landi F.; Gemelli Against COVID-19 Post-Acute Care Study Group Persistent symptoms in patients after acute COVID-19. JAMA 2020,324(6),603-605","journal-title":"JAMA"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/qjmed\/hcaa255","volume":"113","author":"Tale S.","year":"2020","unstructured":"Tale S.; Ghosh S.; Meitei S.P.; Kolli M.; Garbhapu A.K.; Pudi S.; Post-COVID-19 pneumonia pulmonary fibrosis. QJM 2020,113(11),837-838","journal-title":"QJM"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.chest.2021.06.058","volume":"160","author":"Gaurav R.","year":"2021","unstructured":"Gaurav R.; Anderson D.R.; Radio S.J.; Bailey K.L.; England B.R.; Mikuls T.R.; Thiele G.M.; Strah H.M.; Romberger D.J.; Wyatt T.A.; Dickinson J.D.; Duryee M.J.; Katafiasz D.M.; Nelson A.J.; Poole J.A.; IL-33 depletion in COVID-19 lungs. Chest 2021,160(5),1656-1659","journal-title":"Chest"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","volume":"63","author":"Gil C.","year":"2020","unstructured":"Gil C.; Ginex T.; Maestro I.; Nozal V.; Barrado-Gil L.; Cuesta-Geijo M.\u00c1.; Urquiza J.; Ram\u00edrez D.; Alonso C.; Campillo N.E.; Martinez A.; COVID-19: Drug targets and potential treatments. J Med Chem 2020,63(21),12359-12386","journal-title":"J Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.drudis.2015.11.015","volume":"21","author":"Chang C.K.","year":"2016","unstructured":"Chang C.K.; Lo S-C.; Wang Y-S.; Hou M-H.; Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. Drug Discov Today 2016,21(4),562-572","journal-title":"Drug Discov Today"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1128\/AAC.01407-13","volume":"58","author":"Barton C.","year":"2014","unstructured":"Barton C.; Kouokam J.C.; Lasnik A.B.; Foreman O.; Cambon A.; Brock G.; Montefiori D.C.; Vojdani F.; McCormick A.A.; O\u2019Keefe B.R.; Palmer K.E.; Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin Griffithsin in two laboratory rodent models. Antimicrob Agents Chemother 2014,58(1),120-127","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pathogens9040307","volume":"9","author":"Nadeem M.S.","year":"2020","unstructured":"Nadeem M.S.; Zamzami M.A.; Choudhry H.; Murtaza B.N.; Kazmi I.; Ahmad H.; Shakoori A.R.; Origin, potential therapeutic targets and treatment for coronavirus disease (COVID-19). Pathogens 2020,9(4),1-13","journal-title":"Pathogens"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1128\/JVI.00998-13","volume":"87","author":"Adedeji A.O.","year":"2013","unstructured":"Adedeji A.O.; Severson W.; Jonsson C.; Singh K.; Weiss S.R.; Sarafianos S.G.; Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol 2013,87(14),8017-8028","journal-title":"J Virol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","volume":"363","author":"Liu S.","year":"2004","unstructured":"Liu S.; Xiao G.; Chen Y.; He Y.; Niu J.; Escalante C.R.; Xiong H.; Farmar J.; Debnath A.K.; Tien P.; Jiang S.; Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004,363(9413),938-947","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"Xia S.","year":"2020","unstructured":"Xia S.; Liu M.; Wang C.; Xu W.; Lan Q.; Feng S.; Qi F.; Bao L.; Du L.; Liu S.; Qin C.; Sun F.; Shi Z.; Zhu Y.; Jiang S.; Lu L.; Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 2020,30(4),343-355","journal-title":"Cell Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","volume":"150","author":"Lin M-H.","year":"2018","unstructured":"Lin M-H.; Moses D.C.; Hsieh C-H.; Cheng S.C.; Chen Y.H.; Sun C.Y.; Chou C.Y.; Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res 2018,150,155-163","journal-title":"Antiviral Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"Elfiky A.A.","year":"2020","unstructured":"Elfiky A.A.; Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020,253,117592","journal-title":"Life Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.chembiol.2005.01.006","volume":"12","author":"Tanner J.A.","year":"2005","unstructured":"Tanner J.A.; Zheng B.J.; Zhou J.; Watt R.M.; Jiang J.Q.; Wong K.L.; Lin Y.P.; Lu L.Y.; He M.L.; Kung H.F.; Kesel A.J.; Huang J.D.; The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol 2005,12(3),303-311","journal-title":"Chem Biol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1016\/j.ejmech.2011.09.005","volume":"46","author":"Kim M.K.","year":"2011","unstructured":"Kim M.K.; Yu M-S.; Park H.R.; Kim K.B.; Lee C.; Cho S.Y.; Kang J.; Yoon H.; Kim D.E.; Choo H.; Jeong Y.J.; Chong Y.; 2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both Hepatitis C Virus (HCV) and SARS-associated coronavirus (SCV). Eur J Med Chem 2011,46(11),5698-5704","journal-title":"Eur J Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1128\/AAC.00957-12","volume":"56","author":"Adedeji A.O.","year":"2012","unstructured":"Adedeji A.O.; Singh K.; Calcaterra N.E.; DeDiego M.L.; Enjuanes L.; Weiss S.; Sarafianos S.G.; Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob Agents Chemother 2012,56(9),4718-4728","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/ddr.21679","volume":"81","author":"Rothlin R.P.","year":"2020","unstructured":"Rothlin R.P.; Vetulli H.M.; Duarte M.; Pelorosso F.G.; Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Drug Dev Res 2020,81(7),768-770","journal-title":"Drug Dev Res"},{"key":"ref=57","author":"Smith M.D.","year":"2020","unstructured":"Smith M.D.; Smith J.C.; Repurposing therapeutics for COVID-19: Supercomputer-based docking to the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface ChemRxiv 2020","journal-title":"ChemRxiv"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.1021\/acs.jpclett.0c02278","volume":"11","author":"Batra R.","year":"2020","unstructured":"Batra R.; Chan H.; Kamath G.; Ramprasad R.; Cherukara M.J.; Sankaranarayanan S.K.R.S.; Screening of therapeutic agents for COVID-19 using machine learning and ensemble docking studies. J Phys Chem Lett 2020,11(17),7058-7065","journal-title":"J Phys Chem Lett"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"Zhang H.","year":"2020","unstructured":"Zhang H.; Penninger J.M.; Li Y.; Zhong N.; Slutsky A.S.; Angiotensin-Converting Enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med 2020,46(4),586-590","journal-title":"Intensive Care Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/path.2987","volume":"225","author":"W\u00f6sten-van Asperen R.M.","year":"2011","unstructured":"W\u00f6sten-van Asperen R.M.; Lutter R.; Specht P.A.; Moll G.N.; van Woensel J.B.; van der Loos C.M.; van Goor H.; Kamilic J.; Florquin S.; Bos A.P.; Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol 2011,225(4),618-627","journal-title":"J Pathol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","volume":"52","author":"Haschke M.","year":"2013","unstructured":"Haschke M.; Schuster M.; Poglitsch M.; Loibner H.; Salzberg M.; Bruggisser M.; Penninger J.; Kr\u00e4henb\u00fchl S.; Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 2013,52(9),783-792","journal-title":"Clin Pharmacokinet"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Kleine-Weber H.; Schroeder S.; Kr\u00fcger N.; Herrler T.; Erichsen S.; Schiergens T.S.; Herrler G.; Wu N.H.; Nitsche A.; M\u00fcller M.A.; Drosten C.; P\u00f6hlmann S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280.e8","journal-title":"Cell"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biochi.2017.07.016","volume":"142","author":"Shen L.W.","year":"2017","unstructured":"Shen L.W.; Mao H.J.; Wu Y.L.; Tanaka Y.; Zhang W.; TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie 2017,142,1-10","journal-title":"Biochimie"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"104837","DOI":"10.1016\/j.phrs.2020.104837","volume":"157","author":"Maggio R.","year":"2020","unstructured":"Maggio R.; Corsini G.U.; Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacol Res 2020,157,104837","journal-title":"Pharmacol Res"},{"key":"ref=65","author":"Wang X.","year":"2020","unstructured":"Wang X.; Dhindsa R.; Povysil G.; TMPRSS2 transcriptional inhibition as a therapeutic strategy for COVID-19 Preprints Available from: 2020","journal-title":"Preprints"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/2159-8290.CD-20-0451","volume":"10","author":"Stopsack K.H.","year":"2020","unstructured":"Stopsack K.H.; Mucci L.A.; Antonarakis E.S.; Nelson P.S.; Kantoff P.W.; TMPRSS2 and COVID-19: Serendipity or opportunity for intervention? Cancer Discov 2020,10(6),779-782","journal-title":"Cancer Discov"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1517\/13543776.2014.1000303","volume":"25","author":"Couture F.","year":"2015","unstructured":"Couture F.; Kwiatkowska A.; Dory Y.L.; Day R.; Therapeutic uses of furin and its inhibitors: A patent review. Expert Opin Ther Pat 2015,25(4),379-396","journal-title":"Expert Opin Ther Pat"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","volume":"116","author":"Zhou Y.","year":"2015","unstructured":"Zhou Y.; Vedantham P.; Lu K.; Agudelo J.; Carrion R.; Nunneley J.W.; Barnard D.; P\u00f6hlmann S.; McKerrow J.H.; Renslo A.R.; Simmons G.; Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 2015,116,76-84","journal-title":"Antiviral Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.1021\/acs.jmedchem.9b00136","volume":"62","author":"Verdonck S.","year":"2019","unstructured":"Verdonck S.; Pu S-Y.; Sorrell F.J.; Elkins J.M.; Froeyen M.; Gao L.J.; Prugar L.I.; Dorosky D.E.; Brannan J.M.; Barouch-Bentov R.; Knapp S.; Dye J.M.; Herdewijn P.; Einav S.; De Jonghe S.; Synthesis and structure-activity relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as inhibitors of adaptor-associated kinase 1 with antiviral Activity. J Med Chem 2019,62(12),5810-5831","journal-title":"J Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.antiviral.2018.05.001","volume":"155","author":"Pu S-Y.","year":"2018","unstructured":"Pu S-Y.; Xiao F.; Schor S.; Bekerman E.; Zanini F.; Barouch-Bentov R.; Nagamine C.M.; Einav S.; Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Res 2018,155,67-75","journal-title":"Antiviral Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"Richardson P.","year":"2020","unstructured":"Richardson P.; Griffin I.; Tucker C.; Smith D.; Oechsle O.; Phelan A.; Rawling M.; Savory E.; Stebbing J.; Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020,395(10223),e30-e31","journal-title":"Lancet"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"Ou X.","year":"2020","unstructured":"Ou X.; Liu Y.; Lei X.; Li P.; Mi D.; Ren L.; Guo L.; Guo R.; Chen T.; Hu J.; Xiang Z.; Mu Z.; Chen X.; Chen J.; Hu K.; Jin Q.; Wang J.; Qian Z.; Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020,11(1),1620","journal-title":"Nat Commun"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e35069","DOI":"10.1371\/journal.pone.0035069","volume":"7","author":"Wada Y.","year":"2012","unstructured":"Wada Y.; Cardinale I.; Khatcherian A.; Chu J.; Kantor A.B.; Gottlieb A.B.; Tatsuta N.; Jacobson E.; Barsoum J.; Krueger J.G.; Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLoS One 2012,7(4),e35069","journal-title":"PLoS One"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.bbrc.2009.03.063","volume":"382","author":"Ikonomov O.C.","year":"2009","unstructured":"Ikonomov O.C.; Sbrissa D.; Shisheva A.; YM201636, an inhibitor of retroviral budding and PIKfyve-catalyzed PtdIns(3,5)P2 synthesis, halts glucose entry by insulin in adipocytes. Biochem Biophys Res Commun 2009,382(3),566-570","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.bbamcr.2018.10.022","volume":"1866","author":"Penny C.J.","year":"2019","unstructured":"Penny C.J.; Vassileva K.; Jha A.; Yuan Y.; Chee X.; Yates E.; Mazzon M.; Kilpatrick B.S.; Muallem S.; Marsh M.; Rahman T.; Patel S.; Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers. Biochim Biophys Acta Mol Cell Res 2019,1866(7),1151-1161","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"106044","DOI":"10.1016\/j.ijantimicag.2020.106044","volume":"56","author":"Homolak J.","year":"2020","unstructured":"Homolak J.; Kodvanj I.; Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents 2020,56(2),106044","journal-title":"Int J Antimicrob Agents"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1159\/000508247","volume":"181","author":"Seif F.","year":"2020","unstructured":"Seif F.; Aazami H.; Khoshmirsafa M.; Kamali M.; Mohsenzadegan M.; Pornour M.; Mansouri D.; JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol 2020,181(6),467-475","journal-title":"Int Arch Allergy Immunol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s12015-020-09976-7","volume":"16","author":"Ulrich H.","year":"2020","unstructured":"Ulrich H.; Pillat M.M.; CD147 as a Target for COVID-19 treatment: Suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep 2020,16(3),434-440","journal-title":"Stem Cell Rev Rep"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41392-020-0127-9","volume":"5","author":"Zhou W.","year":"2020","unstructured":"Zhou W.; Liu Y.; Tian D.; Wang C.; Wang S.; Cheng J.; Hu M.; Fang M.; Gao Y.; Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther 2020,5(1),18","journal-title":"Signal Transduct Target Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","volume":"395","author":"Shang L.","year":"2020","unstructured":"Shang L.; Zhao J.; Hu Y.; Du R.; Cao B.; On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020,395(10225),683-684","journal-title":"Lancet"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1038\/s41467-020-17834-w","volume":"11","author":"Guo C.","year":"2020","unstructured":"Guo C.; Li B.; Ma H.; Wang X.; Cai P.; Yu Q.; Zhu L.; Jin L.; Jiang C.; Fang J.; Liu Q.; Zong D.; Zhang W.; Lu Y.; Li K.; Gao X.; Fu B.; Liu L.; Ma X.; Weng J.; Wei H.; Jin T.; Lin J.; Qu K.; Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat Commun 2020,11(1),3924","journal-title":"Nat Commun"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1099\/vir.0.061911-0","volume":"95","author":"Hart B.J.","year":"2014","unstructured":"Hart B.J.; Dyall J.; Postnikova E.; Zhou H.; Kindrachuk J.; Johnson R.F.; Olinger G.G.; Frieman M.B.; Holbrook M.R.; Jahrling P.B.; Hensley L.; Interferon-\u03b2 and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014,95(Pt 3),571-577","journal-title":"J Gen Virol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"Rossignol J-F.","year":"2014","unstructured":"Rossignol J-F.; Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res 2014,110,94-103","journal-title":"Antiviral Res"},{"key":"ref=84","author":"Deng X.","year":"2020","unstructured":"Deng X.; Yu X.; Pei J.; Regulation of interferon production as a potential strategy for COVID-19 treatment. arXiv Available from: 2020","journal-title":"arXiv"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41577-020-0320-7","volume":"20","author":"Risitano A.M.","year":"2020","unstructured":"Risitano A.M.; Mastellos D.C.; Huber-Lang M.; Yancopoulou D.; Garlanda C.; Ciceri F.; Lambris J.D.; Complement as a target in COVID-19? Nat Rev Immunol 2020,20(6),343-344","journal-title":"Nat Rev Immunol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"26895","DOI":"10.1039\/D0RA05821A","volume":"10","author":"El-Din Abuo-Rahma G.A.","year":"2020","unstructured":"El-Din Abuo-Rahma G.A.; Mohamed M.F.A.; Ibrahim T.S.; Shoman M.E.; Samir E.; Abd El-Baky R.M.; Potential repurposed SARS-CoV-2 (COVID-19) infection drugs. RSC Advances 2020,10(45),26895-26916","journal-title":"RSC Advances"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12879-017-2253-8","volume":"17","author":"Lin S-C.","year":"2017","unstructured":"Lin S-C.; Ho C-T.; Chuo W-H.; Li S.; Wang T.T.; Lin C-C.; Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect Dis 2017,17(1),144","journal-title":"BMC Infect Dis"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1128\/AAC.03011-14","volume":"58","author":"de Wilde A.H.","year":"2014","unstructured":"de Wilde A.H.; Jochmans D.; Posthuma C.C.; Zevenhoven-Dobbe J.C.; van Nieuwkoop S.; Bestebroer T.M.; van den Hoogen B.G.; Neyts J.; Snijder E.J.; Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014,58(8),4875-4884","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"671498","DOI":"10.3389\/fphar.2021.671498","volume":"12","author":"Alam S.","year":"2021","unstructured":"Alam S.; Sarker M.M.R.; Afrin S.; Richi F.T.; Zhao C.; Zhou J.R.; Mohamed I.N.; Traditional herbal medicines, bioactive metabolites, and plant products against COVID-19: Update on clinical trials and mechanism of actions. Front Pharmacol 2021,12,671498","journal-title":"Front Pharmacol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/10641963.2017.1377218","volume":"40","author":"Hussain M.","year":"2018","unstructured":"Hussain M.; Awan F.R.; Hypertension regulating angiotensin peptides in the pathobiology of cardiovascular disease. Clin Exp Hypertens 2018,40(4),344-352","journal-title":"Clin Exp Hypertens"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1536\/jhj.45.183","volume":"45","author":"Kanda T.","year":"2004","unstructured":"Kanda T.; Takahashi T.; Interleukin-6 and cardiovascular diseases. Jpn Heart J 2004,45(2),183-193","journal-title":"Jpn Heart J"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.bbadis.2019.01.020","volume":"1865","author":"Chen D.","year":"2019","unstructured":"Chen D.; Li Z.; Bao P.; Chen M.; Zhang M.; Yan F.; Xu Y.; Ji C.; Hu X.; Sanchis D.; Zhang Y.; Ye J.; Nrf2 deficiency aggravates Angiotensin II-induced cardiac injury by increasing hypertrophy and enhancing IL-6\/STAT3-dependent inflammation. Biochim Biophys Acta Mol Basis Dis 2019,1865(6),1253-1264","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jir.2010.0073","volume":"31","author":"Guo F.","year":"2011","unstructured":"Guo F.; Chen X-L.; Wang F.; Liang X.; Sun Y-X.; Wang Y-J.; Role of angiotensin II type 1 receptor in angiotensin II-induced cytokine production in macrophages J Interferon Cytokine Res 2011,31(4),351-361","journal-title":"J Interferon Cytokine Res"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"Huang C.","year":"2020","unstructured":"Huang C.; Wang Y.; Li X.; Ren L.; Zhao J.; Hu Y.; Zhang L.; Fan G.; Xu J.; Gu X.; Cheng Z.; Yu T.; Xia J.; Wei Y.; Wu W.; Xie X.; Yin W.; Li H.; Liu M.; Xiao Y.; Gao H.; Guo L.; Xie J.; Wang G.; Jiang R.; Gao Z.; Jin Q.; Wang J.; Cao B.; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020,395(10223),497-506","journal-title":"Lancet"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","volume":"9","author":"Han H.","year":"2020","unstructured":"Han H.; Ma Q.; Li C.; Liu R.; Zhao L.; Wang W.; Zhang P.; Liu X.; Gao G.; Liu F.; Jiang Y.; Cheng X.; Zhu C.; Xia Y.; Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect 2020,9(1),1123-1130","journal-title":"Emerg Microbes Infect"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1161\/01.CIR.0000094737.21775.32","volume":"108","author":"Li S.S.","year":"2003","unstructured":"Li S.S.; Cheng C.W.; Fu C.L.; Chan Y.H.; Lee M.P.; Chan J.W.; Yiu S.F.; Left ventricular performance in patients with severe acute respiratory syndrome: A 30-day echocardiographic follow-up study. Circulation 2003,108(15),1798-1803","journal-title":"Circulation"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/pgmj.2005.037515","volume":"82","author":"Yu C-M.","year":"2006","unstructured":"Yu C-M.; Wong R.S-M.; Wu E.B.; Kong S.L.; Wong J.; Yip G.W.; Soo Y.O.; Chiu M.L.; Chan Y.S.; Hui D.; Lee N.; Wu A.; Leung C.B.; Sung J.J.; Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J 2006,82(964),140-144","journal-title":"Postgrad Med J"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nsb1001-874","volume":"8","author":"He Y.","year":"2001","unstructured":"He Y.; Chipman P.R.; Howitt J.; Bator C.M.; Whitt M.A.; Baker T.S.; Kuhn R.J.; Anderson C.W.; Freimuth P.; Rossmann M.G.; Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat Struct Biol 2001,8(10),874-878","journal-title":"Nat Struct Biol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijcard.2019.07.046","volume":"294","author":"Zanatta A.","year":"2019","unstructured":"Zanatta A.; Carturan E.; Rizzo S.; Basso C.; Thiene G.; Story telling of myocarditis. Int J Cardiol 2019,294,61-64","journal-title":"Int J Cardiol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"107155","DOI":"10.1016\/j.carpath.2019.107155","volume":"44","author":"Razzano D.","year":"2020","unstructured":"Razzano D.; Fallon J.T.; Myocarditis: Somethings old and something new. Cardiovasc 2020,44,107155","journal-title":"Cardiovasc"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","volume":"52","author":"Hirano T.","year":"2020","unstructured":"Hirano T.; Murakami M.; COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020,52(5),731-733","journal-title":"Immunity"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1126\/science.1116480","volume":"309","author":"Li F.","year":"2005","unstructured":"Li F.; Li W.; Farzan M.; Harrison S.C.; Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005,309(5742),1864-1868","journal-title":"Science"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"Kuba K.","year":"2005","unstructured":"Kuba K.; Imai Y.; Rao S.; Gao H.; Guo F.; Guan B.; Huan Y.; Yang P.; Zhang Y.; Deng W.; Bao L.; Zhang B.; Liu G.; Wang Z.; Chappell M.; Liu Y.; Zheng D.; Leibbrandt A.; Wada T.; Slutsky A.S.; Liu D.; Qin C.; Jiang C.; Penninger J.M.; A crucial role of Angiotensin Converting Enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005,11(8),875-879","journal-title":"Nat Med"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/1096-9896(2000)9999:9999<:AID-PATH743>3.0.CO;2-T","volume":"193","author":"Vaarala M.H.","year":"2001","unstructured":"Vaarala M.H.; Porvari K.S.; Kellokumpu S.; Kyll\u00f6nen A.P.; Vihko P.T.; Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J Pathol 2001,193(1),134-140","journal-title":"J Pathol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","volume":"20","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Yan L-M.; Wan L.; Xiang T.X.; Le A.; Liu J.M.; Peiris M.; Poon L.L.M.; Zhang W.; Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020,20(6),656-657","journal-title":"Lancet Infect Dis"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/eurheartj\/ehaa190","volume":"42","author":"Hu H.","year":"2021","unstructured":"Hu H.; Ma F.; Wei X.; Fang Y.; Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J 2021,42(2),206","journal-title":"Eur Heart J"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","volume":"46","author":"Ruan Q.","year":"2020","unstructured":"Ruan Q.; Yang K.; Wang W.; Jiang L.; Song J.; Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020,46(5),846-848","journal-title":"Intensive Care Med"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00059-020-04909-z","volume":"45","author":"Chen C.","year":"2020","unstructured":"Chen C.; Zhou Y.; Wang D.W.; SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz 2020,45(3),230-232","journal-title":"Herz"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s15010-020-01424-5","volume":"48","author":"Zeng J-H.","year":"2020","unstructured":"Zeng J-H.; Liu Y-X.; Yuan J.; Wang F.X.; Wu W.B.; Li J.X.; Wang L.F.; Gao H.; Wang Y.; Dong C.F.; Li Y.J.; Xie X.J.; Feng C.; Liu L.; First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection 2020,48(5),773-777","journal-title":"Infection"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1702090","volume":"378","author":"Kwong J.C.","year":"2018","unstructured":"Kwong J.C.; Schwartz K.L.; Campitelli M.A.; Chung H.; Crowcroft N.S.; Karnauchow T.; Katz K.; Ko D.T.; McGeer A.J.; McNally D.; Richardson D.C.; Rosella L.C.; Simor A.; Smieja M.; Zahariadis G.; Gubbay J.B.; Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018,378(4),345-353","journal-title":"N Engl J Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","volume":"75","author":"Driggin E.","year":"2020","unstructured":"Driggin E.; Madhavan M.V.; Bikdeli B.; Chuich T.; Laracy J.; Biondi-Zoccai G.; Brown T.S.; Der Nigoghossian C.; Zidar D.A.; Haythe J.; Brodie D.; Beckman J.A.; Kirtane A.J.; Stone G.W.; Krumholz H.M.; Parikh S.A.; Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol 2020,75(18),2352-2371","journal-title":"J Am Coll Cardiol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"Tang N.","year":"2020","unstructured":"Tang N.; Li D.; Wang X.; Sun Z.; Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020,18(4),844-847","journal-title":"J Thromb Haemost"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"39353","DOI":"10.1074\/jbc.M508914200","volume":"280","author":"Warner F.J.","year":"2005","unstructured":"Warner F.J.; Lew R.A.; Smith A.I.; Lambert D.W.; Hooper N.M.; Turner A.J.; Angiotensin-Converting Enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem 2005,280(47),39353-39362","journal-title":"J Biol Chem"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"256294","DOI":"10.1155\/2012\/256294","volume":"2012","author":"Tikellis C.","year":"2012","unstructured":"Tikellis C.; Thomas M.C.; Angiotensin-Converting Enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept 2012,2012,256294","journal-title":"Int J Pept"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/j.1440-1681.1995.tb02325.x","volume":"22","author":"Campbell D.J.","year":"1995","unstructured":"Campbell D.J.; Angiotensin Converting Enzyme (ACE) inhibitors and kinin metabolism: Evidence that ACE inhibitors may inhibit a kininase other than ACE. Clin Exp Pharmacol Physiol 1995,22(12),903-911","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1161\/01.HYP.38.1.95","volume":"38","author":"Tom B.","year":"2001","unstructured":"Tom B.; de Vries R.; Saxena P.R.; Danser A.H.; Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade Hypertens 2001,38(1),95-99","journal-title":"Hypertens"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40256-016-0173-4","volume":"16","author":"Taddei S.","year":"2016","unstructured":"Taddei S.; Bortolotto L.; Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs 2016,16(5),309-321","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000368404","volume":"165","author":"Craig T.J.","year":"2014","unstructured":"Craig T.J.; Bernstein J.A.; Farkas H.; Bouillet L.; Boccon-Gibod I.; Diagnosis and treatment of bradykinin-mediated angioedema: Outcomes from an angioedema expert consensus meeting. Int Arch Allergy Immunol 2014,165(2),119-127","journal-title":"Int Arch Allergy Immunol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1139\/y95-114","volume":"73","author":"Parratt J.R.","year":"1995","unstructured":"Parratt J.R.; Vegh A.; Papp J.G.; Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning-a brief review of the evidence. Can J Physiol Pharmacol 1995,73(7),837-842","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/j.1398-9995.2011.02686.x","volume":"66","author":"Maurer M.","year":"2011","unstructured":"Maurer M.; Bader M.; Bas M.; Bossi F.; Cicardi M.; Cugno M.; Howarth P.; Kaplan A.; Kojda G.; Leeb-Lundberg F.; L\u00f6tvall J.; Magerl M.; New topics in bradykinin research. Allergy 2011,66(11),1397-1406","journal-title":"Allergy"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.vph.2005.02.007","volume":"42","author":"Critz S.D.","year":"2005","unstructured":"Critz S.D.; Cohen M.V.; Downey J.M.; Mechanisms of acetylcholine- and bradykinin-induced preconditioning. Vascul Pharmacol 2005,42(5-6),201-209","journal-title":"Vascul Pharmacol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"118A","DOI":"10.1016\/S0002-9149(97)00466-9","volume":"80","author":"Linz W.","year":"1997","unstructured":"Linz W.; Wiemer G.; Sch\u00f6lkens B.A.; Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Am J Cardiol 1997,80(3A),118A-123A","journal-title":"Am J Cardiol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/aps.2009.114","volume":"30","author":"Yan J.T.","year":"2009","unstructured":"Yan J.T.; Wang T.; Wang D.W.; Recombinant adeno-associated virus-mediated human kallikrein gene therapy protects against hypertensive target organ injuries through inhibiting cell apoptosis. Acta Pharmacol Sin 2009,30(9),1253-1261","journal-title":"Acta Pharmacol Sin"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.regpep.2006.11.020","volume":"140","author":"Yao Y-Y.","year":"2007","unstructured":"Yao Y-Y.; Yin H.; Shen B.; Chao L.; Chao J.; Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept 2007,140(1-2),12-20","journal-title":"Regul Pept"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1464-5491.2006.01861.x","volume":"23","author":"Yang J.K.","year":"2006","unstructured":"Yang J.K.; Feng Y.; Yuan M.Y.; Yuan S.Y.; Fu H.J.; Wu B.Y.; Sun G.Z.; Yang G.R.; Zhang X.L.; Wang L.; Xu X.; Xu X.P.; Chan J.C.; Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006,23(6),623-628","journal-title":"Diabet Med"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"e13034","DOI":"10.1111\/obr.13034","volume":"21","author":"Kassir R.","year":"2020","unstructured":"Kassir R.; Risk of COVID-19 for patients with obesity. Obes Rev 2020,21(6),e13034","journal-title":"Obes Rev"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/pmic.200500638","volume":"6","author":"Wan J.","year":"2006","unstructured":"Wan J.; Sun W.; Li X.; Ying W.; Dai J.; Kuai X.; Wei H.; Gao X.; Zhu Y.; Jiang Y.; Qian X.; He F.; Inflammation inhibitors were remarkably up-regulated in plasma of severe acute respiratory syndrome patients at progressive phase. Proteomics 2006,6(9),2886-2894","journal-title":"Proteomics"},{"key":"ref=128","first-page":"151","volume":"33","author":"Lima-Mart\u00ednez M.M.","year":"2021","unstructured":"Lima-Mart\u00ednez M.M.; Carrera Boada C.; Madera-Silva M.D.; Mar\u00edn W.; Contreras M.; COVID-19 and diabetes: A bidirectional relationship Clin Investig Arterioscler 2021,33(3),151-157","journal-title":"Clin Investig Arterioscler"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"e3377","DOI":"10.1002\/dmrr.3377","volume":"37","author":"Zhou Y.","year":"2021","unstructured":"Zhou Y.; Chi J.; Lv W.; Wang Y.; Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev 2021,37(2),e3377","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"107637","DOI":"10.1016\/j.jdiacomp.2020.107637","volume":"34","author":"Cuschieri S.","year":"2020","unstructured":"Cuschieri S.; Grech S.; COVID-19 and diabetes: The why, the what and the how. J Diabetes Complications 2020,34(9),107637","journal-title":"J Diabetes Complications"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","volume":"17","author":"Lim S.","year":"2021","unstructured":"Lim S.; Bae J.H.; Kwon H.S.; Nauck M.A.; COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat Rev Endocrinol 2021,17(1),11-30","journal-title":"Nat Rev Endocrinol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.2337\/dc08-0138","volume":"31","author":"Kornum J.B.","year":"2008","unstructured":"Kornum J.B.; Thomsen R.W.; Riis A.; Lervang H-H.; Sch\u00f8nheyder H.C.; S\u00f8rensen H.T.; Diabetes, glycemic control, and risk of hospitalization with pneumonia: A population-based case-control study. Diabetes Care 2008,31(8),1541-1545","journal-title":"Diabetes Care"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"e000181","DOI":"10.1136\/bmjdrc-2015-000181","volume":"4","author":"Martins M.","year":"2016","unstructured":"Martins M.; Boavida J.M.; Raposo J.F.; Froes F.; Nunes B.; Ribeiro R.T.; Macedo M.P.; Penha-Gon\u00e7alves C.; Diabetes hinders community-acquired pneumonia outcomes in hospitalized patients. BMJ Open Diabetes Res Care 2016,4(1),e000181","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41430-020-0652-1","volume":"74","author":"Gupta R.","year":"2020","unstructured":"Gupta R.; Hussain A.; Misra A.; Diabetes and COVID-19: Evidence, current status and unanswered research questions. Eur J Clin Nutr 2020,74(6),864-870","journal-title":"Eur J Clin Nutr"},{"key":"ref=135","unstructured":"Symptoms of COVID-19. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42399-020-00363-4","author":"Sanyaolu A.","year":"2020","unstructured":"Sanyaolu A.; Okorie C.; Marinkovic A.; Patidar R.; Younis K.; Desai P.; Hosein Z.; Padda I.; Mangat J.; Altaf M.; Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020,1-8","journal-title":"SN Compr Clin Med"},{"key":"ref=137","unstructured":"COVID-19. Available from: http:\/\/www.bccdc.ca\/health-info\/diseases-conditions\/covid-19"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1172\/JCI88876","volume":"127","author":"McLaughlin T.","year":"2017","unstructured":"McLaughlin T.; Ackerman S.E.; Shen L.; Engleman E.; Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest 2017,127(1),5-13","journal-title":"J Clin Invest"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"108166","DOI":"10.1016\/j.diabres.2020.108166","volume":"164","author":"Chee Y.J.","year":"2020","unstructured":"Chee Y.J.; Ng S.J.H.; Yeoh E.; Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract 2020,164,108166","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4093\/dmj.2020.0091","volume":"44","author":"Kim N.Y.","year":"2020","unstructured":"Kim N.Y.; Ha E.; Moon J.S.; Lee Y.H.; Choi E.Y.; Acute hyperglycemic crises with coronavirus disease-19: Case reports. Diabetes Metab J 2020,44(2),349-353","journal-title":"Diabetes Metab J"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.dsx.2019.03.022","volume":"13","author":"Stratigou T.","year":"2019","unstructured":"Stratigou T.; Vallianou N.; Vlassopoulou B.; Tzanela M.; Vassiliadi D.; Ioannidis G.; Tsagarakis S.; DKA cases over the last three years: has anything changed? Diabetes Metab Syndr 2019,13(2),1639-1641","journal-title":"Diabetes Metab Syndr"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa360","volume":"105","author":"Palermo N.E.","year":"2020","unstructured":"Palermo N.E.; Sadhu A.R.; McDonnell M.E.; Diabetic ketoacidosis in COVID-19: unique concerns and considerations. J Clin Endocrinol Metab 2020,105(8),1-11","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.2337\/diabetes.53.8.2079","volume":"53","author":"Stentz F.B.","year":"2004","unstructured":"Stentz F.B.; Umpierrez G.E.; Cuervo R.; Kitabchi A.E.; Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004,53(8),2079-2086","journal-title":"Diabetes"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/dom.14057","volume":"22","author":"Li J.","year":"2020","unstructured":"Li J.; Wang X.; Chen J.; Zuo X.; Zhang H.; Deng A.; COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020,22(10),1935-1941","journal-title":"Diabetes Obes Metab"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/imj.14207","volume":"49","author":"Azzam O.","year":"2019","unstructured":"Azzam O.; Prentice D.; Lactation ketoacidosis: An easily missed diagnosis. Intern Med J 2019,49(2),256-259","journal-title":"Intern Med J"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fpsyt.2019.00363","volume":"10","author":"Kov\u00e1cs Z.","year":"2019","unstructured":"Kov\u00e1cs Z.; D\u2019Agostino D.P.; Diamond D.; Kindy M.S.; Rogers C.; Ari C.; Therapeutic potential of exogenous ketone supplement induced ketosis in the treatment of psychiatric disorders: Review of current Literature. Front Psychiatry 2019,10,363","journal-title":"Front Psychiatry"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.metabol.2015.12.007","volume":"65","author":"Nyenwe E.A.","year":"2016","unstructured":"Nyenwe E.A.; Kitabchi A.E.; The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism 2016,65(4),507-521","journal-title":"Metabolism"},{"key":"ref=148","unstructured":"Metformin, an oral anti-diabetic drug, may reduce mortality in women infected by COVID-19. Available from: https:\/\/www.firstpost.com\/health\/metformin-an-oral-anti-diabetic-drug-may-reduce-mortality-in-women-infected-by-covid-19-claims-study-8519791.html"},{"key":"ref=149","author":"Tripathi K.D.","year":"2013","unstructured":"Tripathi K.D.; Essentials of Medical Pharmacology 7th Ed; Jaypee Brothers Medical Publishers (P): New Delhi 2013","journal-title":"Essentials of Medical Pharmacology 7th Ed; Jaypee Brothers Medical Publishers (P): New Delhi"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557522666220201154845","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200755\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557522666220201154845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T16:55:17Z","timestamp":1665680117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200755\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":149,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557522666220201154845","relation":{},"ISSN":["1389-5575"],"issn-type":[{"type":"print","value":"1389-5575"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}